Publication | Closed Access

Discovery of T-1101 tosylate as a first-in-class clinical candidate for Hec1/Nek2 inhibition in cancer therapy

First-in-class Clinical CandidateT-1101 TosylateHec1/nek2 InhibitionMedicineOncogenic AgentReceptor Tyrosine KinaseImmunologyImmune Checkpoint InhibitorCancer BiologyCancer TreatmentOncologyCell BiologyCancer ResearchTumor Biology